secwatch.observer — SEC 8-K summary
======================================

Issuer:     Liminatus Pharma, Inc. (LIMN)
CIK:        0001971387
Form:       8-K
Filed at:   2025-07-03T23:59:59+00:00
Accession:  0001104659-25-065663
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Liminatus Pharma forms consortium for pancreatic cancer blood diagnostic with >95% sensitivity
--------------------------------------------------------------------------------

- Signed MOU with Samda Biolab and INNOCS AI to develop a blood-based diagnostic kit for early pancreatic cancer detection.
- Combined CA19-9 and INNOCS platform achieved >95% sensitivity and >99% specificity in a 1,086-subject cohort.
- Liminatus will lead regulatory filings with FDA and KMFDS upon commercialization phase.
- Global pancreatic cancer diagnostics market projected at $3B by 2026; blood-based segment >$700M.
- Consortium to leverage AI, biomarker platform, and Liminatus's regulatory/commercial infrastructure.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1971387/000110465925065663/0001104659-25-065663-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1971387/000110465925065663/tm2519876d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-065663

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer